RE:RE:A positiveFrom the Zack's article, it sounds like the potential funding for PHI testing is contingent on the FDA approval of Biogen's aducanumab, which would essentially validated amyloid beta as a target for AD treatment.
While the aducanumab data shows limited efficacy, it does show significant levels of benefit.
Personally, I wish the PHI would just launch, but it's not my $10M, so it is easy for me to say that. It would probably be a tough process if aducanumab were denied approval, basically starting from scratch in validating amyloid beta as a target to the approval authorities. By leveraging Biogen's effort, I would guess that the PMN310 pathway to market would be more efficient for said potential investor.
These are just my opinions based on public documents. There may be more happening behind the scenes.